Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Canaccord Genuity lowers BioNTech's target price to $132

Canaccord Genuity lowers BioNTech's target price to $132

格隆汇格隆汇2026/10/15 08:37
Show original
Golden Ten Data October 15|Canaccord Genuity has lowered the target price of BioNTech from $136 to $132, maintaining a "Buy" rating.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Barclays (BCS.US) bets on a merger between Tesla (TSLA.US) and SpaceX (SPCX.US) in December, but prediction markets give only a 19% probability.

Barclays analyst Levy predicts that Tesla and SpaceX may merge before December to achieve AI integration. However, data from Kalshi and Polymarket indicate that the probability of a short-term merger is very low, with the market favoring such a move after 2027.

智通财经•2026/10/15 09:07

Barclays (BCS.US) bearish on Dell (DELL.US): No inflection point in AI spending, memory costs are the main reason

Barclays has downgraded Dell from Overweight to Neutral and lowered the target price. The institution noted that corporate AI spending remains low and revenue growth is driven by memory shortages, which stands in stark contrast to Michael Dell’s optimistic outlook.

智通财经•2026/10/15 09:06